BRPI0818324B8 - formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica - Google Patents

formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica

Info

Publication number
BRPI0818324B8
BRPI0818324B8 BRPI0818324A BRPI0818324A BRPI0818324B8 BR PI0818324 B8 BRPI0818324 B8 BR PI0818324B8 BR PI0818324 A BRPI0818324 A BR PI0818324A BR PI0818324 A BRPI0818324 A BR PI0818324A BR PI0818324 B8 BRPI0818324 B8 BR PI0818324B8
Authority
BR
Brazil
Prior art keywords
presentation
variant
preparation
pharmaceutical composition
formulation containing
Prior art date
Application number
BRPI0818324A
Other languages
English (en)
Portuguese (pt)
Inventor
Del Rio Alessandra
Samaritani Fabrizio
Richard Joel
Agostinetto Rita
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of BRPI0818324A2 publication Critical patent/BRPI0818324A2/pt
Publication of BRPI0818324B1 publication Critical patent/BRPI0818324B1/pt
Publication of BRPI0818324B8 publication Critical patent/BRPI0818324B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0818324A 2007-11-01 2008-10-29 formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica BRPI0818324B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28
PCT/EP2008/064679 WO2009056569A1 (en) 2007-11-01 2008-10-29 Lh liquid formulations

Publications (3)

Publication Number Publication Date
BRPI0818324A2 BRPI0818324A2 (pt) 2017-05-16
BRPI0818324B1 BRPI0818324B1 (pt) 2019-12-24
BRPI0818324B8 true BRPI0818324B8 (pt) 2021-05-25

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818324A BRPI0818324B8 (pt) 2007-11-01 2008-10-29 formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica

Country Status (25)

Country Link
US (1) US8664369B2 (cg-RX-API-DMAC7.html)
EP (1) EP2219607B1 (cg-RX-API-DMAC7.html)
JP (1) JP5551601B2 (cg-RX-API-DMAC7.html)
KR (1) KR101513181B1 (cg-RX-API-DMAC7.html)
CN (1) CN101842083B (cg-RX-API-DMAC7.html)
AU (1) AU2008320844B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818324B8 (cg-RX-API-DMAC7.html)
CA (1) CA2700662C (cg-RX-API-DMAC7.html)
CY (1) CY1113121T1 (cg-RX-API-DMAC7.html)
DK (1) DK2219607T3 (cg-RX-API-DMAC7.html)
EA (1) EA019432B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010224A (cg-RX-API-DMAC7.html)
ES (1) ES2393233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120660T1 (cg-RX-API-DMAC7.html)
IL (1) IL205105A (cg-RX-API-DMAC7.html)
MX (1) MX2010004639A (cg-RX-API-DMAC7.html)
MY (1) MY153976A (cg-RX-API-DMAC7.html)
NZ (1) NZ583991A (cg-RX-API-DMAC7.html)
PL (1) PL2219607T3 (cg-RX-API-DMAC7.html)
PT (1) PT2219607E (cg-RX-API-DMAC7.html)
RS (1) RS52566B (cg-RX-API-DMAC7.html)
SI (1) SI2219607T1 (cg-RX-API-DMAC7.html)
UA (1) UA101484C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009056569A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001907B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
BR112012000177B1 (pt) * 2009-07-06 2021-06-01 Sanofi-Aventis Deutschland Gmbh Formulação farmacêutica aquosa contendo metionina, processo para sua preparação, uso da mesma e medicamento para tratar diabetes mellitus
CA2780043C (en) * 2009-11-13 2019-01-29 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR112015013223A2 (pt) * 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
UA61053C2 (en) * 1995-03-21 2003-11-17 Applied Research Systems Stable liquid pharmaceutical compositions, method for its production and delivery form
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
AU2004204720B2 (en) * 2003-01-08 2009-08-06 Novartis Vaccines And Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
JP4699991B2 (ja) * 2003-04-02 2011-06-15 アレス トレーディング ソシエテ アノニム 非イオン性界面活性剤を一緒に伴うｆｓｈ及びｌｈの液体医薬組成物

Also Published As

Publication number Publication date
PL2219607T3 (pl) 2012-12-31
EA201070549A1 (ru) 2010-10-29
KR101513181B1 (ko) 2015-04-21
EA019432B1 (ru) 2014-03-31
US20100261649A1 (en) 2010-10-14
CN101842083B (zh) 2012-11-14
RS52566B (sr) 2013-04-30
JP2011502968A (ja) 2011-01-27
NZ583991A (en) 2012-02-24
HRP20120660T1 (hr) 2012-09-30
HK1145443A1 (en) 2011-04-21
SI2219607T1 (sl) 2012-09-28
WO2009056569A1 (en) 2009-05-07
PT2219607E (pt) 2012-08-31
MY153976A (en) 2015-04-30
CA2700662C (en) 2015-10-13
CY1113121T1 (el) 2016-04-13
MX2010004639A (es) 2010-08-04
BRPI0818324A2 (pt) 2017-05-16
IL205105A0 (en) 2010-11-30
AU2008320844A1 (en) 2009-05-07
WO2009056569A9 (en) 2010-01-21
AU2008320844B2 (en) 2013-08-29
IL205105A (en) 2015-04-30
CA2700662A1 (en) 2009-05-07
EP2219607A1 (en) 2010-08-25
ZA201001907B (en) 2011-05-25
BRPI0818324B1 (pt) 2019-12-24
US8664369B2 (en) 2014-03-04
UA101484C2 (en) 2013-04-10
EP2219607B1 (en) 2012-08-15
KR20100088147A (ko) 2010-08-06
DK2219607T3 (da) 2013-06-17
CN101842083A (zh) 2010-09-22
ES2393233T3 (es) 2012-12-19
JP5551601B2 (ja) 2014-07-16
ECSP10010224A (es) 2010-07-30

Similar Documents

Publication Publication Date Title
BRPI0818324B8 (pt) formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
BRPI0910461B8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
HK1247856A1 (zh) 羟丙基β-环糊精组合物及方法
CO6321221A2 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico
UY30315A1 (es) Formulacion de medicamento liquida
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
EP4110301A4 (en) Pharmaceutical composition for oral administration
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
WO2009084036A3 (en) Composition for treatment of viral infections
CL2004002030A1 (es) Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
EA201200754A1 (ru) Традиционное китайское лекарственное средство, содержащее экстракты дан-шен (danshen) и сан-ки (sanqi), и его применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF